Surgery for Recurrent Pancreatic Cancer: Is It Effective?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Jul 19

PMID 31315222

Citations 34

Authors

Lucia Moletta

Simone Serafini

Michele Valmasoni

Elisa Sefora Pierobon

Alberto Ponzoni

Cosimo Sperti

Affiliations

Soon will be listed here.

Abstract

Despite improvements to surgical procedures and novel combinations of drugs for adjuvant and neoadjuvant therapies for pancreatic adenocarcinoma, the recurrence rate after radical surgery is still high. Little is known about the role of surgery in the treatment of isolated recurrences of pancreatic cancer. The aim of this study was to review the current literature dealing with surgery for recurrent pancreatic cancer in order to examine its feasibility and effectiveness. An extensive literature review was conducted according to the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and 14 articles dealing with re-resections for recurrent pancreatic adenocarcinoma were analyzed, focusing on the characteristics of the primary neoplasm and its recurrence, the surgical procedures used, and patient outcomes. Data were retrieved on a total of 301 patients. The interval between surgery for primary pancreatic cancer and the detection of a recurrence ranged from 2 to 120 months. The recurrence was local or regional in 230 patients, and distant in 71. The median overall survival was 68.9 months (range 3-152) after resection of the primary tumor, and 26.0 months (range 0-112) after surgery for recurrent disease. The disease-free interval after the resection of recurrences was 14.2 months (range 4-29). Although data analysis was performed on a heterogeneous and limited number of patients, some of these may benefit from surgery for isolated recurrence of pancreatic adenocarcinoma. Further studies are needed to identify these cases.

Citing Articles

Multimodal treatment combining neoadjuvant therapy, laparoscopic subtotal distal pancreatectomy and adjuvant therapy for pancreatic neck-body cancer: Case series.

Li J, Wang X, Wang Y, Chen K, Li G, Long Y World J Gastrointest Surg. 2025; 17(1):97897.

PMID: 39872794 PMC: 11757209. DOI: 10.4240/wjgs.v17.i1.97897.

Oncointerpreter.ai enables interactive, personalized summarization of cancer diagnostics data.

Tripathi A, Ecker B, Boland P, Ghodoussipour S, Riedlinger G, De S J Am Med Inform Assoc. 2024; 32(1):129-138.

PMID: 39535891 PMC: 11648722. DOI: 10.1093/jamia/ocae284.

A Review of the Indications, Outcomes, and Postoperative Management After Total and Completion Pancreatectomy for Pancreatic Cancer: More Is Not Necessarily Better.

Oppat K, Bennett F, Maithel S Surg Clin North Am. 2024; 104(5):1049-1064.

PMID: 39237163 PMC: 11889495. DOI: 10.1016/j.suc.2024.04.012.

Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma.

Poiset S, Shah S, Cappelli L, Anne P, Mooney K, Werner-Wasik M Radiat Oncol. 2024; 19(1):65.

PMID: 38812040 PMC: 11138072. DOI: 10.1186/s13014-024-02457-y.

Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.

Gu X, Majumder J, Taratula O, Kuzmov A, Garbuzenko O, Pogrebnyak N Int J Mol Sci. 2024; 25(10).

PMID: 38791582 PMC: 11122428. DOI: 10.3390/ijms25105545.

References

Primrose J . Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation. Gut. 2002; 50(1):1-5. PMC: 1773068. DOI: 10.1136/gut.50.1.1. View

Klinkenbijl J, Tjioe M, Jeekel J . Treatment of locoregional recurrence after intentional curative resection of pancreatic cancer. Hepatogastroenterology. 1992; 39(5):429-32. View

Weitz J, Koch M, Debus J, Hohler T, Galle P, Buchler M . Colorectal cancer. Lancet. 2005; 365(9454):153-65. DOI: 10.1016/S0140-6736(05)17706-X. View

Seiler C, Wagner M, Bachmann T, Redaelli C, Schmied B, Uhl W . Randomized clinical trial of pylorus-preserving duodenopancreatectomy versus classical Whipple resection-long term results. Br J Surg. 2005; 92(5):547-56. DOI: 10.1002/bjs.4881. View

Ferrone C, Kattan M, Tomlinson J, Thayer S, Brennan M, Warshaw A . Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol. 2005; 23(30):7529-35. PMC: 3903268. DOI: 10.1200/JCO.2005.01.8101. View

Wilkowski R, Thoma M, Bruns C, Duhmke E, Heinemann V . Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP. 2006; 7(1):34-40. View

Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S . Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006; 10(4):511-8. DOI: 10.1016/j.gassur.2005.09.016. View

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K . Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297(3):267-77. DOI: 10.1001/jama.297.3.267. View

Kleeff J, Reiser C, Hinz U, Bachmann J, Debus J, Jaeger D . Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg. 2007; 245(4):566-72. PMC: 1877037. DOI: 10.1097/01.sla.0000245845.06772.7d. View

10.

Seelig M, Chromik A, Weyhe D, Muller C, Belyaev O, Mittelkotter U . Pancreatic redo procedures: to do or not to do -- this is the question. J Gastrointest Surg. 2007; 11(9):1175-82. DOI: 10.1007/s11605-007-0159-2. View

11.

Riall T, Lillemoe K . Underutilization of surgical resection in patients with localized pancreatic cancer. Ann Surg. 2007; 246(2):181-2. PMC: 1933567. DOI: 10.1097/SLA.0b013e31811eaa2c. View

12.

Valentini V, Morganti A, Macchia G, Mantini G, Mattiucci G, Brizi M . Intraoperative radiation therapy in resected pancreatic carcinoma: long-term analysis. Int J Radiat Oncol Biol Phys. 2008; 70(4):1094-9. DOI: 10.1016/j.ijrobp.2007.07.2346. View

13.

Scheele J, Stangl R, Altendorf-Hofmann A, Gall F . Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery. 1991; 110(1):13-29. View

14.

Katz M, Wang H, Fleming J, Sun C, Hwang R, Wolff R . Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009; 16(4):836-47. PMC: 3066077. DOI: 10.1245/s10434-008-0295-2. View

15.

Seelig M, Janot M, Chromik A, Herzog T, Belyaev O, Weyhe D . Redo-surgery following curative resection of pancreatic carcinoma: the difference between true and suspected recurrence. Dig Surg. 2009; 26(3):222-8. DOI: 10.1159/000219332. View

16.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

17.

Fatima J, Schnelldorfer T, Barton J, Wood C, Wiste H, Smyrk T . Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg. 2010; 145(2):167-72. DOI: 10.1001/archsurg.2009.282. View

18.

Dunschede F, Will L, von Langsdorf C, Mohler M, Galle P, Otto G . Treatment of metachronous and simultaneous liver metastases of pancreatic cancer. Eur Surg Res. 2010; 44(3-4):209-13. DOI: 10.1159/000313532. View

19.

Didolkar M, Coleman C, Brenner M, Chu K, Olexa N, Stanwyck E . Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg. 2010; 14(10):1547-59. DOI: 10.1007/s11605-010-1323-7. View

20.

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View